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Background: Early diagnosis of immune heparin-induced thrombocytopenia (HIT) is challenging. HemosIL®
AcuStar HIT and heparin-induced multiple electrode aggregometry (HIMEA) were recently proposed as rapid
diagnostic methods.
Objectives: We conducted a study to assess performances of AcuStar HIT-IgG (PF4-H) and AcuStar HIT-Ab (PF4-H).
The secondary objective was to compare the performances of the combination of Acustar HIT and HIMEA with
standardised clinical diagnosis.
Methods: Sera of 104 suspected HIT patients were retrospectively tested with AcuStar HIT. HIMEA was performed on
available sera (n = 81). The clinical diagnosis was established by analysing in a standardized manner the patient’s
medical records. These tests were also comparedwith PF4-Enhanced®, LTA, and SRA in subsets of patients. Thresholds
were determined using ROC curve analysis with clinical outcome as reference.
Results: Using the recommended thresholds (1.00 AU), the negative predictive value (NPV) of HIT-IgG and HIT-Ab
were 100.0% (95% CI: 95.9%-100.0% and 95.7%-100.0%). The positive predictive value (PPV) were 64.3% (95% CI:
35.1%-87.2.2%) and 45.0% (95% CI: 23.2%-68.6%), respectively. Using our thresholds (HIT-IgG: 2.89 AU, HIT-Ab:
9.41 AU), NPV of HIT-IgG and HIT-Ab were 100.0% (95% CI: 96.0%-100.0% and 96.1%-100.0%). PPV were 75.0% (95%
CI: 42.7%-94.5%) and 81.8% (95% CI: 48.3%-97.7%), respectively. Of the 79 patients with a medium-high pretest
probability score, 67 were negative using HIT-IgG (PF4-H) test at our thresholds. HIMEA was performed on HIT-IgG
positive patients. Using this combination, only one patient on 79 was incorrectly diagnosed.
Conclusion: Acustar HIT showed good performances to exclude the diagnosis of HIT. Combination with HIMEA
improves PPV.© 2013 Elsevier Ltd. All rights reserved.Introduction
Immune heparin-induced thrombocytopenia (HIT) is a severe
immune-mediated adverse effect of heparin treatment [1,2]. Early
diagnosis is essential and both missed diagnosis and erroneous
diagnosis should be avoided [3]. A wrong diagnosis may lead to a
discontinuation of the treatment with heparin and substitution by
an anticoagulant which is actually not required. This substitution is
expensive and could be associated with an increased risk of bleeding
(10-20% of major haemorrhage) without effective antidote [3,4]. Whileartment of Pharmacy, Rue de
92; fax: +32 81 724299.
et).
rights reserved.
sment of the performances o
tudy, Thromb Res (2013), hearly diagnosis of HIT is essential to improve clinical management of
patients, it remains challenging, especially in critically ill patients, in
intensive care [5]. The current diagnostic relies on the use of a clinical
scoring algorithm (“4T’s rule”) togetherwith immunological and platelet
activation assays [1,2,6]. This combination improves HIT diagnosis
compared to its components considered independently [7]. However,
the scoring systemhas to be used carefully andmay require some exten-
sive documentation of the patient medical history [8]. Non-specific
enzyme-immunoassay (EIA) (IgG/A/M) and IgG-specific EIA can rule
out the occurrence of HIT (their negative predictive value (NPV) is
equal to 99% [2]). However, they are still lacking specificity (50-90%)
and need a careful standardization of the optical density (OD) ranges [9].
HemosIL® AcuStar HIT and heparin-induced multiple electrode
aggregometry (HIMEA) were recently proposed as new rapid methods
for the diagnosis of HIT.f AcuStar HIT and the combination with heparin-induced multiple
ttp://dx.doi.org/10.1016/j.thromres.2013.06.004
2 V. Minet et al. / Thrombosis Research xxx (2013) xxx–xxxThe HemosIL® AcuStar HIT-IgG (PF4-H) and AcuStar HIT-Ab
(PF4-H) tests were developed by Legnani et al. as rapid, automated
semi-quantitative immunoassays with very high sensitivity (100%)
that can reliably be used to rule out the occurrence of a HIT, and a spec-
ificity of 81-96% [10]. In addition, Elalamy et al. showed that HIMEA
with the Multiplate® analyzer has a similar sensitivity for detection of
the presence of HIT platelet activating antibodies as the conventional
light transmission aggregometry (LTA) performed in citrated platelet-
rich plasma (PRP) [11]. Consequently, HIMEA was proposed as a new
diagnostic tool that simplifies the process of HIT diagnosis compared
with LTA [11,12].
We assessed the performances of AcuStar HIT-IgG (PF4-H),
AcuStar HIT-Ab (PF4-H), and HIMEA and compared them with the
ones of PF4-Enhanced®, Light Transmission Aggregometry (LTA).
These performances were assessed against the 14C-Serotonin Release
Assay (SRA), and a clinical diagnosis. Subsequently, we retrospectively
assessed this combination in the HIT diagnosis strategy proposed by
Greinacher et al. (Fig. 1) [2].
Materials and Methods
Healthy subjects
The platelets were obtained from healthy volunteers O Rh+/-
blood group donors who did not take any medicine which could
potentially affect their platelet function for 10 days before the blood
sampling. Platelet donors were selected on the basis of a good reactivity
to HIT antibodies. No donor had to be excluded of the study because they
all presented normal aggregationwith the following reagents: adenosine
diphosphate (ADP), collagen, arachidonic acid (AA) or thrombin receptor
activating peptide (TRAP).
Patients
After approval by the local ethics committee, 106 patients with
suspected diagnosis of HIT between October 2006 and July 2011 at
CHU UCL Mont-Godinne-Dinant (Université Catholique de Louvain,
Yvoir, Belgium) were included in this study (these include 104 inpa-
tients, 2 outpatients, among them 94 patients underwent surgery). The
primary diagnosiswas based on a rapidly decreasing platelet count occur-
ring in hospitalised patients and on the result of the “4T’s rule” (whichFig. 1. Diagnostic algorithm for immune HIT.
Please cite this article as:Minet V, et al, Assessment of the performances o
electrode aggregometry: A retrospective study, Thromb Res (2013), htakes into consideration four criteria: a Thrombocytopenia, and its Timing,
the occurrence of a Thrombosis and the exclusion of other causes of
thrombocytopenia). Blood samples of these patients were sent to the He-
matology Laboratory for laboratory assays. Samples for the study were
collected independently of patient underlying disease. Samples were ei-
ther tested as stored samples (samples before January 2008) or in real
time (from January 2008). Routine laboratory diagnosis was based on
PF4-Enhanced® (GTI Diagnostics, Waukesha, WI, USA) and LTA.
Criteria from the ACCP (American College of Chest Physicians)
guidelines were used to make the clinical diagnosis of HIT: (1)
Thrombocytopenia, defined as at least a 30% decline in the platelet
count, with a platelet count increase after heparin cessation; (2) Timing
of platelet count fall after the initiation of heparin occurring between 4
and 14 days, or occurringwithin 24 to 48 hours (in case of prior heparin
exposure within 30 days); and (3) lack of other, predominant causes of
thrombocytopenia [13,14]. Other causes of thrombocytopenia analysed
in this study were: scalable neoplasia, lower extremity arterial disease,
current pregnancy or postpartum, autoimmune disease, sepsis,
disseminated intravascular coagulation, intra-aortic balloon pump
counterpulsation, multitransfusion, multi-trauma, shock syndrome, in-
flammatory syndrome and drug-induced thrombocytopenia (quinolone,
β-lactam, vancomycin, teicoplanin, rifampicin, isoniazid, amphotericin,
fluconazole, chemotherapy, anti-GPIIb IIIa; furosemide and proton
pump inhibitor).
All those 3 clinical criteria have to be fulfilled for the confirmation of
clinical HIT diagnosis. Themedical history of each patientwas extensively
analysed. The following information was taken into consideration: pa-
tient’s medical history, types (fractionated vs. unfractionated) and doses
of heparin administered, thrombotic complications, alternative diagnoses,
therapeutic attitude, clinical and platelet count evolution, co-suspected
medications, and physician’s diagnoses [14]. These clinical criteria were
independently assessed by two investigators (VM and FM), not aware
of the results of the laboratory assays. Clinical diagnoses made by these
2 local investigators were 100% concordant.
Blood sampling and handling
Bloodwas collectedwith a 20 gauge needle via atraumatic antecubital
venipuncture into polyethylene terephthalate tubes Venosafe® (Terumo
Europe, Leuven, Belgium) containing buffered sodium citrate (109 mM,
nine parts of blood to one part sodium citrate solution) or 25 μg/mL
recombinant hirudin (Verum Diagnostica GmbH, Munich, Germany,
1:10 v/v). The blood group was chosen as O. A discard tube was used
to avoid thromboplastin contamination. Sera were used for all assays
described in this study except for LTA.
When serum was used, we waited 30 min before performing cen-
trifugation and 15 min after centrifugation to reduce the interference
of thrombin. We also controlled the absence of spontaneous aggrega-
tion bymixing patients’ sera with whole blood from healthy volunteers
without any agonist. For LTA, PRP was obtained from the supernatant
fraction after centrifugation at 200 g during 10 min at room tempera-
ture. The remaining blood was centrifuged at 2,200 g during 15 min
at room temperature and the supernatant gave the platelet-poor plasma
(PPP).
Laboratory testing
Immunoassays
The presence of anti-PF4-heparin antibodies was investigated in 106
serum samples by using PF4-Enhanced® (GTI Diagnostics, Waukesha,
WI, USA), AcuStar HIT-IgG (PF4-H) and AcuStar HIT-Ab (PF4-H)
(Instrumentation Laboratory, Bedford, MA, USA) [10] according to
themanufacturers’s recommendations. PF4-Enhanced®was performed
in real time on fresh sera whereas AcuStar HIT-IgG (PF4-H) and AcuStar
HIT-Ab (PF4-H) were performed afterwards on frozen sera (-80 °C).
PF4-Enhanced® is an enzyme-linked immunosorbent assay (ELISA).f AcuStar HIT and the combination with heparin-induced multiple
ttp://dx.doi.org/10.1016/j.thromres.2013.06.004
3V. Minet et al. / Thrombosis Research xxx (2013) xxx–xxxThe spectrophotometry threshold used in our study is the one
recommended by the manufacturer (0.400 OD).
The HemosIL® AcuStar HIT-IgG (PF4-H) and HIT-Ab (PF4-H) are
two chemiluminescent two-step immunoassays consisting of magnetic
particles coated with PF4 complexed to polyvinyl sulfonate which
bind the anti-PF4/H antibodies from the sample. This assay has been
described by Legnani et al. [10]. The threshold used in our study
(recommended by the manufacturer) is 1.00 AU.Platelet reactivity and heparin-induced LTA
The platelet reactivity of the healthy donors was assessed by LTA.
Aggregation tests were performed according to the Born's turbidi-
metric method with a PACKS-4® aggregometer (Helena, Beaumont,
Texas, USA) [15]. This assay has been described by Mullier et al. [16].
Platelet reactivity was performed by using three different agonists:
ADP (final concentration: 5 μM), collagen (type 1, final concentration:
from 40 and 190 μg/mL) (Biodata Corporation, Horsham, PA, USA)
and AA (final concentration: 0.5 mg/mL) (Biodata Corporation, Horsham,
PA, USA). Heparin-induced LTA was performed with a range of un-
fractionated heparin (UFH) final concentrations (0.5 IU/mL, 1 IU/mL,
10 IU/mL and 500 IU/mL) using unfractionated sodium heparin
5000 IU/mL (Heparin Leo®, Leo Pharma, Lier, Belgium) diluted
with physiological saline (B Braun Medical, Diegem, Belgium).
The endpoint used for our study was the percentage of aggregation.
The result was considered positive when platelet aggregation occurred
in the presence of low UFH concentration (percentage of aggregation
higher than 20% at 0.5 IU/mL or 1 IU/mL) but was partially inhibited
(percentage of aggregation lower than 20%) by a high concentration
of UFH (500 IU/mL).Heparin-induced multiple electrode aggregometry (HIMEA)
HIMEA was performed retrospectively on all available frozen
(-80 °C for maximum 18 months) sera (n = 81). Multiple electrode
aggregometry (MEA) is amethod for the assessment of platelet function
in whole blood (Multiplate® analyzer; Dynabyte, Munich, Germany)
[17].
MEA is based on the principle of impedance aggregometry. Whole
blood samples from three healthy volunteers O Rh+/- blood group
were collected by venipuncture in hirudin tube.
The platelet reactivity of the healthy donors was assessed by
Multiplate® using four different agonists: ADP (final concentration:
6.5 μM), collagen (type 1, final concentration: 3.2 μg/mL) (Dynabyte,
Munich, Germany), AA (final concentration: 0.5 mM) (Dynabyte,
Munich, Germany) andTRAP-6 (final concentration: 32 μM) (Dynabyte,
Munich, Germany). Our procedure is similar from the one described
byMorel-Kopp et al. [12] but differs from volumes used. In our protocol,
we mixed 300 μL of saline with 150 μL of whole blood from healthy
donors, 150 μL of serum from HIT patients and 50 μL of UFH solution
(Heparin Leo®). We used three final UFH concentrations of 1 IU/mL,
10 IU/mL and 385 IU/mL as well as with the addition of normal pooled
plasma instead of serum of the patient. Heparin concentrations were
chosen based on preliminary studies comparing 0.5 IU/mL and 1 IU/mL
UFH (n = 32). We used 385 IU/mL UFH instead of 100 IU/mL UFH,
often used in the literature, to avoid an additional dilution of the stock
solution (5000 IU/mL). The HIMEA was expressed using the area under
the aggregation curve (AUC). The result was considered to be positive
when the platelet aggregation occurred in the presence of low
heparin concentration (1 IU/mLUFHor 10 IU/mLUFH) butwaspartially
inhibited (reduction > 80%) by a high concentration of heparin
(385 IU/mL UFH). The negative control should be b100 AU.14C-serotonin release assay (SRA)
The SRA was performed retrospectively on frozen (-80 °C for
maximum 18 months) sera.Please cite this article as:Minet V, et al, Assessment of the performances o
electrode aggregometry: A retrospective study, Thromb Res (2013), hThe SRAwas carried out according to previously published protocols
in all available samples (n = 45) [18]. Two out of these 45 patients
were excluded because of lack of clinical data.
Data analysis
Statistical analysis was performed using Medcalc software (version
10.4.8) (Gent, Belgium).
The AUC was computed with the corresponding 95% confidence
intervals (95% CI). The sensitivity and specificity of HemosIL® AcuStar
HIT-IgG (PF4-H) and HIT-Ab (PF4-H) were assessed using both
SRA and clinical diagnosis as gold standards. We also assessed the
performances of the methods using ROC curves.
Results
Of the 106 patients suspected of having developed HIT, 104
completed the clinical follow-up. Seventy three men and thirty one
women aged from26 to 101 years (median age 70 years),were included
in our study. Nine patients (9/79 i.e. 11.4%) were considered to have
developed a HIT based on our clinical diagnosis. Of these, 5 patients
experienced a thrombosis (2 venous thrombosis, 2 arterial thrombosis,
and1patient hadboth a venous and arterial thrombosis). OneHIT patient
died during his hospitalisation.
Determination of optimal thresholds from ROC curves (using clinical
diagnosis as gold standard) and assessment of diagnostic performances
Compared to clinical diagnosis, we determined the optimal thresholds
of AcuStar HIT-IgG (PF4-H), AcuStar HIT-Ab (PF4-H), PF4-Enhanced®,
HIMEA at 1 IU/mL UFH and HIMEA at 10 IU/mL UFH using ROC curve
analyses. These thresholds were 2.89 AU, 9.41 AU, 1.32 OD, 276 AU and
183 AU respectively. At the optimal cut-off provided by ROC Curves,
we noted that the sensitivity of AcuStar HIT-IgG (PF4-H) and HIT-Ab
(PF4-H) is respectively 100.0% (95% CI: 59.0%-100.0%) and 100.0% (95%
CI: 66.4%-100.0%); a high sensitivity is a priority for screening assays.
When clinical diagnosis was used as the reference, NPV and sensitivity
were of 100.0% except for HIMEA at 10 IU/mL UFH for which the
NPV and sensitivity were respectively 97.0% (95% CI: 91.4%-99.6%) and
75.0% (95% CI: 34.9%-96.8%). The specificity reached 96.8% (95% CI:
91.0%-99.3%), 97.9% (95% CI: 92.6%-99.7%), 96.8% (95% CI: 89.6%-98.8%),
97.3% (95% CI: 90.5%-99.7%), and 89.0% (95% CI: 79.5%-95.1%), respective-
ly. The positive predictive values (PPV)were 75.0% (95% CI: 42.7%-94.5%),
81.8% (95% CI: 48.3%-97.7%), 75.0% (95% CI: 42.7%-94.5%), 80.0% (95% CI:
44.2%-96.3%) and 42.9% (95% CI: 17.1%-65.5%) (Table 1). Sensitivity, spec-
ificity and PPV were lower with the HIMEA at 10 IU/mL UFH than with
HIMEA at 1 IU/mL UFH, consequently we used the results of HIMEA at
1 IU/mL UFH. The recommended threshold for AcuStar HIT-IgG (PF4-H),
AcuStar HIT-Ab (PF4-H) (i.e. 1.00 AU) and PF4-Enhanced® (i.e. 0.400
OD) yielded lower specificities of 94.7% (95% CI: 88.1%-98.3%), 88.4%
(95% CI: 80.2%-94.1%), and 85.3% (95% CI: 76.5%-91.7%). The PPV were
64.3% (95% CI: 35.1%-87.2%), 45.0% (95% CI: 23.2%-68.6%) and 39.1%
(95% CI: 19.8%-61.6%), respectively. The disagreements between the
different tests are shown in Table 1.
Moreover, a preliminary study did not show any difference between
0.5 IU/mL and 1 IU/mL UFH (n = 32, p = 0.22).
Performances of the combination of AcuStar HIT-IgG (PF4-H) and HIMEA
according the diagnostic algorithm proposed by Greinacher et al. [2] and
using the optimised thresholds
Twenty five patients (25/104 i.e. 24%) included in the study were
classified as low according to the 4T’s pre-test probability (PTP) rule,
76 as medium (73%), and 3 as high (3%).
Of the seventy nine patients with a medium-high pretest prob-
ability score, AcuStar HIT-IgG (PF4-H) at our threshold excludedf AcuStar HIT and the combination with heparin-induced multiple
ttp://dx.doi.org/10.1016/j.thromres.2013.06.004
Table 1
Comparison of PF4-Enhanced®, HemosIL® AcuStar HIT-IgG (PF4-H) and HIT-Ab (PF4-H), LTA, HIMEA and SRA with the clinical diagnosis. Only patients with available clinical
diagnosis were considered (n = 104).
Clinical
diagnosis
Sensitivity,
% (95%CI)
Specificity,
% (95%CI)
PPV,
% (95%CI)
NPV,
% (95%CI)
Negative Positive
PF4-Enhanced
(n = 104)
Threshold : >0.40 OD Negative 81 0 100.0
(66.4-100.0)
85.3
(76.5-91.7)
39.1
(19.8-61.6)
100.0
(95.5-100.0)Positive 14 9
PF4-Enhanced
(n = 104)
Threshold : >1.32 OD Negative 92 0 100.0
(66.4-100.0)
96.8
(89.6-98.8)
75.0
(42.7-94.5)
100.0
(96.0-100.0)Positive 3 9
AcuStar IgG
(n = 104)
Threshold : >1.00 AU Negative 90 0 100.0
(66.4-100.0)
94.7
(88.1-98.3)
64.3
(35.1-87.2)
100.0
(95.9-100.0)Positive 5 9
AcuStar IgG
(n = 104)
Threshold : >2.89 AU Negative 92 0 100.0
(59.0-100.0)
96.8
(91.0-99.3)
75.0
(42.7-94.5)
100.0
(96.0-100.0)Positive 3 9
AcuStar IgG
(n = 79)
Threshold : >1.00 AU Negative 65 0 100
(62.9-100.0)
92.9
(83.4-97.3)
64.3
(35.6-86.0)
100.0
(93.0-100.0)Positive 5 9
AcuStar IgG
(n = 79)
Threshold : >2.89 AU Negative 67 0 100.0
(62.9-100.0)
95.7
(87.2-98.9)
75.0
(42.8-93.3)
100.0
(93.2-100.0)Positive 3 9
AcuStar Ab
(n = 104)
Threshold : >1.00 AU Negative 84 0 100.0
(66.4-100.0)
88.4
(80.2-94.1)
45.0
(23.2-68.6)
100.0
(95.7-100.0)Positive 11 9
AcuStar Ab
(n = 104)
Threshold : >9.41 AU Negative 93 0 100.0
(66.4-100.0)
97.9
(92.6-99.7)
81.8
(48.3-97.7)
100.0
(96.1-100.0)Positive 2 9
AcuStar Ab
(n = 79)
Threshold : >1.00 AU Negative 60 0 100
(62.9-100.0)
85.7
(74.8-92.6)
47.4
(25.2-70.5)
100.0
(92.5-100.0)Positive 10 9
AcuStar Ab
(n = 79)
Threshold : >9.41 AU Negative 62 0 100.0
(62.9-100.0)
88.6
(78.2-94.6)
52.9
(28.5-76.1)
100.0
(92.7-100.0)Positive 8 9
HIMEA
(n = 81)
Threshold : >276 AU
(1 IU/mL UFH)
Negative 71 0 100.0
(63.1-100.0)
97.3
(90.5-99.7)
80.0
(44.2-96.3)
100.0
(96.1-100.0)Positive 2 8
HIMEA
(n = 81)
Threshold : >183 AU
(10 IU/mL UFH)
Negative 65 2 75.0
(34.9-96.8)
89.0
(79.5-95.1)
42.9
(17.1-65.5)
97.0
(91.4-99.6)Positive 8 6
LTA
(n = 46)
Threshold: >20%
(0.5 and 1 IU/mL UFH)
Negative 38 0 100.0
(39.8-100.0)
90.5
(77.9-97.4)
50.0
(26.1-74.0)
100.0
(95.8-100.0)Positive 4 4
SRA
(n = 43)
Threshold: >20%
(0.1 and 0.3 IU/mL UFH)
Negative 36 1 80.0
(28.4-99.5)
94.7
(82.3-99.4)
66.7
(28.2-85.3)
97.3
(92.6-99.8)Positive 2 4
AcuStar IgG + HIMEA
(n = 78)
Threshold : >2.89 AU
+ > 276 AU (1 IU/mL UFH)
Negative 69 0 100.0
(59.7-100.0)
98.6
(91.2-99.9)
88.9
(50.7-99.4)
100
(93.4-100.0)Positive 1 8
4 V. Minet et al. / Thrombosis Research xxx (2013) xxx–xxxthe presence of HIT in 67 of these patients (Fig. 2). NPV of HIT-IgG
(PF4-H) and HIT-Ab (PF4-H) assays for patients with a medium-
high pretest probability, were 100.0% (95% CI: 93.2%-100.0%)Fig. 2. Flow chart with results according to the HIT dia
Please cite this article as:Minet V, et al, Assessment of the performances o
electrode aggregometry: A retrospective study, Thromb Res (2013), hand 100.0% (95% CI: 92.7%-100%). The PPV of HIT-IgG (PF4-H)
assay and HIT-Ab (PF4-H) were 75.0% (95% CI: 42.8%-93.3%) and
52.9 (95% CI: 28.5%-76.1%) (Table 1).gnosis strategy proposed by Greinacher et al. [2].
f AcuStar HIT and the combination with heparin-induced multiple
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5V. Minet et al. / Thrombosis Research xxx (2013) xxx–xxxAmong the 12 positive AcuStar HIT-IgG (PF4-H), 9 patients were
clinically confirmed HIT. 11 positive AcuStar HIT-IgG (PF4-H) were
tested on HIMEA, 1 patient could not be tested (no sample available).
HIMEA at 1 IU/mL UFH diagnosed correctly 10 patients of the 11 posi-
tive AcuStar HIT-IgG (PF4-H). HIMEA at 1 IU/mL UFH confirmed the
absence of HIT in 2 out of 3 patients not presenting a HIT (Table 1).
The third non-HIT patient showed a platelet aggregation at 1 IU/mL
UFH slightly above the threshold of 276 AU (306 AU). The sensitivity,
specificity, PPV and NPV of this combination using our thresholds, for
the 78 patientswith amedium-high pretest probability and sample avail-
able, were 100.0% (95% CI: 59.7%-100.0%), 98.6% (95% CI: 91.2%-99.9%),
88.9% (95% CI: 50.7%-99.4%) and 100.0% (95% CI: 93.4%-100.0%), respec-
tively. Over the 104 patients, one patient was incorrectly diagnosed
using our approach.
The individual cases considered to be HIT as well as SRA positive
cases considered not to be HIT, are described in details in Table 3.
Other analyses
Comparison of AcuStar HIT-IgG (PF4-H), AcuStar HIT-Ab (PF4-H) and
PF4-Enhanced®
We have performed a comparison of the ROC curves for AcuStar
HIT-IgG (PF4-H), AcuStar HIT-Ab (PF4-H) and PF4-Enhanced® before
and after the optimization. Before optimization, the AUC was signifi-
cantly higher for AcuStar HIT-IgG (PF4-H) compared to AcuStar HIT-
Ab (PF4-H) and PF4-Enhanced® (p = 0.0118 and 0.0017, respectively).
The optimization of our thresholds improved significantly the AUC
of AcuStar HIT-Ab (PF4-H) and PF4-Enhanced® (p = 0.0017 and
0.0009, respectively) but not the one of AcuStar HIT-IgG (PF4-H)
(p = 0.1551). After the optimization, the differences were not statisti-
cally significant between the 3 tests (p > 0.05).
Comparison of HIMEA with LTA
HIMEA and LTA were performed on the same samples of 45 patients
with a suspected HIT. Compared to the clinical diagnosis, HIMEA at
1 IU/mL UFH, HIMEA at 10 IU/mL UFH and LTA showed, respectively,
a sensitivity of 100.0% (95% CI: 63.1%-100.0%), 75.0% (95% CI: 34.9%-
96.8%) and 100.0% (95% CI: 39.8%-100.0%) and their specificity were
97.3% (95% CI: 90.5%-99.7%), 89.0% (95% CI: 79.5%-95.1%) and 90.5%
(95% CI: 77.9%-97.4%). The comparison of ROC curves did not show any
statistically significant difference (p = 0.67).
Comparison with SRA
The SRA is one of the two gold standards (the second is the heparin
induced platelet activation (HIPA) for the diagnosis of HIT) [19]. The
SRA and the clinical diagnosis provided discordant results in 3 patients
(out of 43 patients with completed clinical follow-up) (Table 2). Two
of these 3 patients were positive with SRA and but considered not to
have developed HIT according to our clinical diagnosis.
Discussion
In this study, we compared the performances of AcuStar HIT-IgG
(PF4-H), AcuStar HIT-Ab (PF4-H), new automated semi-quantitative
immunoassays, with the ones of PF4-Enhanced® as screening tests
for immune heparin-induced thrombocytopenia (HIT). We also devel-
oped HIMEA and compared its performances to LTA, as confirmation
tests for the diagnosis of HIT. The reference used to confirm diagnosis
of HIT was the clinical diagnosis as SRA does not entirely solve the diffi-
cult challenge of appropriate HIT diagnosis [18]. In addition, SRA does
not entirely solve the issue of HIT misdiagnosis [14,20]. Our SRA proto-
col was different from the one performed by Gruel et al. (different tem-
perature and incubation time, different steps of wash and incubation
time) [21]. The threshold used by Warkentin et al. (≥50%) differs
from the threshold considered in our study (>20%) [22]. Consequently
data of SRA in our study cannot be compared to other laboratories, asPlease cite this article as:Minet V, et al, Assessment of the performances o
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explained by the absence of systematic use of at least two suitable
donors in order to control sufficient reactivity of platelets, the absence
of standardized quality control and the exclusion of intermediate or
non-specific results in studies [20]. The performances of the combina-
tion of AcuStar HIT-IgG and HIMEA for rapid diagnosis of HIT were
also studied.
We showed that before redetermination of the thresholds, AUC of
the ROC curve was significantly higher for AcuStar HIT-IgG (PF4-H)
in comparison with AcuStar HIT-Ab (PF4-H) and PF4-Enhanced®.
The new thresholds obtained by comparing the performances of these
methods to the clinical diagnosis were higher than those recommended
by themanufacturer. The thresholds observed are assay-dependent but
most important is the choice of the gold standard used to determine
these thresholds. The manufacturers provided thresholds following a
study on healthy subjects and not on patients suspected of having
developed HIT. The optimization of thresholds improves significantly
the AUC of AcuStar HIT-Ab (PF4-H) and PF4-Enhanced®. After the
optimization, sensitivity and NPV reached 100.0% for all three tests.
The specificity reached 96.8% (95% CI: 91.0%-99.3%), 97.9% (95% CI:
92.6%-99.7%), and 96.8% (95% CI: 89.6%-98.8%), respectively. The PPV
were 75.0%, 81.8% and 75.0%, respectively (Table 1). No statistically sig-
nificant difference was observed between these 3 tests. However, from
a practical perspective AcuStar HIT-IgG (PF4-H) and AcuStar HIT-Ab
(PF4-H) have a running-time of about 30 min compared to 2-3 hours
of ELISA assays (such as PF4-Enhanced®). In addition, this fully auto-
mated machine can be run for a single sample testing. Consequently,
considering these beneficial aspects, we suggest that this new immuno-
logical assay could be widely used to screen patients with a suspected
HIT.
In our study, AcuStar HIT-IgG (PF4-H) and AcuStar HIT-Ab (PF4-H)
showed the same sensitivity as reported by Legnani et al. [10]. The use
of local thresholds markedly improves the specificity of AcuStar
HIT-Ab (PF4-H) from 81.2% (95% CI: 71.3%-88.8%) in Legnani study
to 97.9% (95% CI: 92.6%-99.7%). Our results confirm that the
IgG-specific EIA is more specific than the polyspecific assays [23–25]
in the absence of optimization.
The magnitude of a positive result (in optical density (OD) units)
and the inhibition of reactivity at high heparin concentration are the
two features of EIA reactivity that predict for presence of HIT antibodies.
The probability of anti-PF4/heparin antibodies of being responsible for
the low platelet count or new thrombosis increases with themagnitude
of the EIA OD result [8,9,22,24,26]. However, the interpretation of ELISA
test results according to a fixed OD threshold is associated to the prob-
lem that OD units are non-standardized units. Theymight differ consid-
erably across photometers according to (i) the wavelength-dependent
coefficient of extinction of the materials and fluids, (ii) the concentra-
tion of the molecules in the fluid and (iii) the thickness of the assessed
fluid layer [9]. Consequently, there is no clear threshold to distinguish
between clinically relevant and non-relevant antibodies. For example,
the literature reports contradictory results on the association between
anti-PF4/heparin antibodieswith a 0.40 b OD b 1.00 in the PF4/heparin
EIA with a positive SRA [22,27,28]. As long as there is no standard
for anti-PF4/heparin antibodies, the OD of the ELISA could be used as
an estimate for the likelihood of a clinically relevant antibody only.
Finally, the threshold may depend on the population characteris-
tics [28]. For example, the 97.5% percentile OD value of sera from
patients before cardiac surgery was described as 0.74 [28]. This is likely
explained by recent exposure to heparin, e.g. during coronary angiogra-
phy [9]. In this population, increasing the OD threshold did not improve
the usefulness of HIT EIA’s screening [28]. In the present study, we
have also developed HIMEA, a technique recently proposed by 2 differ-
ent teams for the rapid confirmation of the diagnosis of HIT [11,12].
HIMEA assay is based on the presence of a platelet aggregation at
1 IU/mL UFH or 10 IU/mL UFH with a significant (>80%) reduction at
385 IU/mL UFH. This high concentration leads to a dissociation of thef AcuStar HIT and the combination with heparin-induced multiple
ttp://dx.doi.org/10.1016/j.thromres.2013.06.004
Table 2
Comparison of PF4-Enhanced®, HemosIL® AcuStar HIT-IgG (PF4-H) and HIT-Ab (PF4-H), HIMEA and LTA with SRA.
SRA Sensitivity,
% (95%CI)
Specificity,
% (95%CI)
PPV,
% (95%CI)
NPV,
% (95%CI)
Threshold : >20%
(0.1 and 0.3 IU)
Negative Positive
PF4-Enhanced
(n = 45)
Threshold : >0.400 OD Negative 32 2 66.7
(22.3-95.7)
82.1
(66.5-92.5)
36.4
(10.1-70.8)
94.1
(80.3-99.3)Positive 7 4
PF4-Enhanced
(n = 45)
Threshold : >1.32 OD Negative 36 2 66.7
(22.3-95.7)
92.3
(79.1-98.4)
57.1
(18.4-90.1)
94.7
(82.0-99.4)Positive 3 4
AcuStar IgG
(n = 45)
Threshold : >1.00 AU Negative 36 2 66.7
(22.3-95.7)
92.3
(79.1-98.4)
57.1
(18.4-90.1)
94.7
(82.0-99.4)Positive 3 4
AcuStar IgG
(n = 45)
Threshold : >2.89 AU Negative 37 2 66.7
(22.3-95.7)
94.9
(82.7-99.4)
66.7
(18.8-96.9)
94.9
(82.7-99.4)Positive 2 4
AcuStar Ab
(n = 45)
Threshold : >1.00 AU Negative 34 2 66.7
(22.3-95.7)
87.2
(72.6-95.7)
44.4
(12.3-80.6)
94.4
(81.3-99.3)Positive 5 4
AcuStar Ab
(n = 45)
Threshold : >9.41 AU Negative 37 2 66.7
(22.3-95.7)
94.9
(82.7-99.4)
66.7
(18.8-96.9)
94.9
(82.7-99.4)Positive 2 4
HIMEA
(n = 34)
Threshold : >276 AU
(1 IU/mL UFH)
Negative 26 2 60.0
(14.7-94.7)
89.7
(72.6-97.8)
50.0
(9.48-90.6)
92.9
(76.5-99.1)Positive 3 3
HIMEA
(n = 34)
Threshold : >183 AU
(10 IU/mL UFH)
Negative 26 2 60.0
(14.7-94.7)
89.7
(72.6-97.8)
50.0
(9.48-90.6)
92.9
(76.5-99.1)Positive 3 3
LTA
(n = 32)
Threshold : >20%
(0.5 and 1 IU/mL UFH)
Negative 24 4 75.0
(19.4-99.4)
85.7
(67.3-96.0)
42.9
(9.89-81.6)
96.0
(79.1-99.9)Positive 1 3
6 V. Minet et al. / Thrombosis Research xxx (2013) xxx–xxxcomplex Ig-PF4-heparin and is therefore used to enhance the specificity
of all platelet activation tests [2]. HIMEA at 1 IU/mL UFH offers better
sensitivity and specificity than HIMEA at 10 IU/mL UFH. We have also
compared the performances of HIMEA at 1 IU/mL UFH with the stan-
dard LTA, as confirmation tests for the diagnosis of HIT on 45 suspected
HIT patients. Both showed sensitivity of 100.0%. LTA performed in this
study showed higher sensitivity in comparison with previous reports.
However, these results should be confirmed in a larger series of patients.
The specificity of HIMEA at 1 IU/mL UFH (i.e. 97.3%) is higher than LTA
at 0.5 and 1 IU/mL UFH (i.e. 90.5%) although not significant. Galea et al.
have recently shown that HIMEA at 1 IU/mL UFH is more sensitive
(81% vs. 76%) and more specific (99% vs. 96%) than LTA, in comparison
to SRA [18]. In addition, LTA requires both experience, as well as a
specific expertise and is time-consuming (turn-around-time of about
90 min), which limits its routine use [12]. On the contrary, the use of
HIMEA which requires whole blood provides results within 45 min
and is an accessible assay to a large number of laboratories [11,12].
A limitation for performing of HIMEA is the immediate availability of
a healthy compatible blood group donor. Results were also compared
with SRA assay [29], on a limited series of patients. SRA also suf-
fers from a series of well-known limitations: it is time-consuming,Table 3
Clinical and laboratory data for the 9 patients with a positive diagnosis of HIT and the 2 SR
Patient Laboratory assays
Immunological assays Platelet functional assays
PF4-
Enhanced®
(AU)
AcuStar HIMEA LTA
IgG
(AU)
Ab
(AU)
1 IU/mL
(AU)
10 IU/mL
(AU)
385 IU/mL
(AU)
1 >3 57.73 >128 495 612 48 /
2 2.798 40.94 68.29 714 197 20 /
3 >3 74.39 >128 335 84 0 /
4 2,061 7.11 20.95 660 62 0 positi
5 >3 >128 >128 946 586 97 /
6 >3 37.17 35.1 339 202 34 /
7 1.5 4.45 11.86 - - - positi
8 >3 61.15 108.91 338 216 95 positi
9 >3 >128.00 >128.00 303 184 0 positi
10 0.353 0.03 0.79 151 174 27 positi
11 0.117 0.03 0.56 66 101 0 negat
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available in routine clinical laboratories. Some concerns about inter-
laboratory variability and lack of standardization with SRA have also
been described [30,31]. In addition, previous studies have already
shown undetected cases by SRA [29,30,32] due to the fact that HIT anti-
bodies to PF4 are heterogeneous regarding their affinity and specificity
for target antigens [33,34]. Consequently, validation and standardiza-
tion of SRA is still required before considering it as the gold standard
for the diagnosis HIT [20]. This gold standard assay is still required
to avoid missed diagnosis [30] and overdiagnosis of HIT [3]. Finally,
we tested the algorithm recently proposed by Greinacher et al. [2].
As shown in Fig. 1, this algorithm includes a PTP, a highly sensitive
immunological assay and a specific confirmatory assay to improve the
diagnosis of HIT.
In the present study, no patient with a low PTP (n = 25) presented
a HIT confirming the effectiveness of the 4T’s rule at reducing the num-
ber of laboratory tests (hence the costs). These patients should remain
on heparin and no subsequent laboratory assay should be performed
[2]. In addition, all these patients tested negative with AcuStar HIT-IgG
(PF4-H) and AcuStar HIT-Ab (PF4-H) demonstrating the high specificity
of these tests. Among the 79 patients with a medium-high PTP, AcuStarA positive cases considered not to be HIT. (ND = Not determined).
Clinical data
SRA 4T's Clinical evolution from the HIT suspicion to the
discharge from hospital
Clinical
diagnosis
Stop
heparin
Platelet count
increase
Thrombotic
complications
/ 5 + + - HIT
/ 5 + + - HIT
/ 5 + + - HIT
ve / 8 + + - HIT
positive 5 + ND (death) +
(venous and arterial)
HIT
positive 7 + + + (venous) HIT
ve positive 5 + + - HIT
ve positive 7 + + + (venous) HIT
ve negative 6 + + + (arterial) HIT
ve positive 7 + - - No HIT
ive positive 3 - - - No HIT
f AcuStar HIT and the combination with heparin-induced multiple
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7V. Minet et al. / Thrombosis Research xxx (2013) xxx–xxxHIT-IgG (PF4-H) excluded the diagnosis of HIT in 67 of them. Among
the remaining 12 patients with a positive AcuStar HIT-IgG (PF4-H), 9
of them had a clinically confirmed HIT. HIMEA allowed the exclusion
of a diagnosis of HIT in 2 out of 3 patients who did not actually develop
HIT.
We have enrolled patients with suspected HIT regardless of their
underlying disease or the indication for the treatment with heparin.
The performances of our methods may also depend on the patient’s
underlying condition e.g. pathologies requiring major surgery or
hospitalisation in intensive care units. This could limit the generalization
of our results and the use of our thresholds. Indeed, the threshold of
AcuStar depends both on the instrumentation used to perform the test
and on the population characteristics.
One of the strengths of our study relies on the comparison of the
performances of the assays against a standardized clinical diagnosis.
Most of the studies published so far simply assessed the correlation
of the results obtained with PF4/heparin EIA ODs and washed platelet
activation assays.
Our study suffers from several limitations. Firstly, our study was
conducted retrospectively, design which can be associated with some
(mostly historical) biases (e.g. lack of documentation of patientmedical
history, recollection biases…). Secondly, our study was conducted in
one laboratory which does not allow for inter-laboratory comparisons.
Thirdly, the size of our cohort is limited (it is in the same range
or even larger than many prior studies conducted in the field).
For that reason, we could not really study the extent and impact of
misclassification associated with the use of a higher threshold than
the ones recommended by the manufacturer. A selection bias may
have affected our study considering that not all patients with a positive
HIT EIA had confirmatory SRA. Samples were either tested as stored
samples or in real time, which may affect the results as the influence
of storage has not yet been studied. HIMEA and SRA were performed
using different platelet donors at different times. Finally, we used a
differentHIMEAprotocol than the oneused in recently published proto-
cols [11,12]. The threshold depends on variables like: volume of whole
blood of the healthy subject, volume of sample of patients, volume
and concentration of heparin, duration of the measurement and the
platelet reactivity of the healthy donors. For example, we used a higher
dilution of patient sample than described in the literature [11,12]. This
could affect the sensitivity of the tests. However, in the present series,
HIMEA correctly detected all (but one, due to an insufficient amount
of sample) patients who developed a HIT.
Ideally, a multicentre study with a larger sample size using
a standardized HIMEA procedure should be conducted. It should
also be noted that HIMEA currently suffers from the absence of a
positive control. Multiple positive controls have been described in
the literature (Polyclonal antibodies to PF4 (Hyphen), positive plas-
ma from a known confirmed HIT patient [11], confirmed anti-PF4-H
platelet activating antibodies [12], antibodies cross-reacting with
the major antigen in HIT [35], and murine monoclonal antibody
that mimics heparin-induced thrombocytopenia antibodies [36]).
However, there is no current consensus on the use of these positive
controls.
Conclusion
In our retrospective study, we demonstrated that the combination
of AcuStar HIT-IgG and HIMEA with optimized thresholds proves to
be useful for the rapid and accurate diagnosis of immune HIT. However,
the demonstration of this effectiveness should be confirmed in large
multicentre prospective study.
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